Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Rio Tinto Stock Jumps as Strong Earnings, Higher Dividend and AI Metal Demand Boost Outlook 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Arm Holdings Q1 Earnings Beat Estimates, Strong Q2 Outlook Fails to Lift ARM Stock 
SAN DIEGO, May 08, 2018 -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its first quarter financial results on Monday, May 14, 2018 before the open of the U.S. financial markets. Company management will host a conference call and webcast on Monday, May 14, 2018 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss the results and provide a corporate update.
Interested parties may access the call by dialing toll-free (844) 358-9116 from the US or (209) 905-5951 internationally and using conference ID 8255679.
The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event.
About aTyr Pharma
aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr’s clinical stage ATYR1923 candidate is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr’s preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 250 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit http://www.atyrpharma.com.
IMMEDIATE RELEASE
Contact:
Mark Johnson
Sr. Director, Investor Relations
[email protected]
858-223-1163
